ORIGINAL ANALYSIS
PDF DOWNLOAD
EXTERNAL LINK
POST
Insight: original analysis
This Week’s Dose: It was a relatively quiet week in Washington with the House of Representatives in recess and the Senate enmeshed in the impeachment trial. Activity is sure to pick up as soon as House members are back in town next week.
Insight: original analysis
Rodney Whitlock and Rachel Stauffer offer a deep dive into what 2020 has in store for the issues of drug pricing and surprise billing.
Insight: original analysis
Congress is back in session following the holiday recess, though the exact Senate schedule remains uncertain as lawmakers negotiate the details of President Trump’s impeachment trial.
Insight: original analysis
A Busy Week to End 2019. Sort of.
Insight: original analysis
House Democrats passed a sweeping drug pricing reform package and key House and Senate committees announced a surprise billing deal.
Insight: original analysis
Congress is back in town with just two weeks to address government funding and many healthcare issues. More proposals are emerging on drug pricing and surprise billing, and the House Judiciary Committee took up impeachment.
Insight: original analysis
Last Week to Address Government Funding and the Extenders.
Insight: original analysis
A House Vote on Prescription Drug Pricing Reforms Slips as We Approach a One Week Recess in the House.
Insight: original analysis
The House Ways and Means Committee completed its markup of H.R. 3, but floor consideration was pushed until mid-November. Seema Verma appeared before the House Energy and Commerce Oversight and Investigations Subcommittee.
Insight: original analysis
Administrator Verma is testifying, and the debate on prescription drug pricing reforms continues.
Insight: original analysis
This Week’s Dose: The House is moving ahead on Speaker Nancy Pelosi’s drug pricing proposal.
Insight: original analysis
Congress is back for a six week stretch. And the Healthcare Preview podcast is now available on Sound Cloud.
Insight: original analysis
Lawmakers came with big ambitions for 2019, but we are headed into 2020 with two major health policies left on life support and many healthcare programs nearing expiration.
Insight: original analysis
Congress is out on a two recess, but the effects of the impeachment inquiry will have long lasting impacts.
Insight: original analysis
This Week’s Dose: Speaker Pelosi’s announcement of an impeachment inquiry dominated the news this week, but what does that mean for health care policy?
Insight: original analysis
Congress has one last week in session before a two-week recess.
Insight: original analysis
This Week’s Dose: Speaker Pelosi released her long-awaited drug pricing bill, and the House Energy and Commerce Committee questioned drug companies’ financial motivations during a hearing this week.
Insight: original analysis
On September 19, 2019, the Speaker of the US House of Representatives released a proposal to contain federal and individual spending on prescription drugs, joining Administration and Senate efforts to address prescription drug pricing. This article contemplates the likelihood of a drug pricing package and how it could come together.
Insight: original analysis
The Government Funding Deadline is Quickly Approaching…
Insight: original analysis
This Week’s Dose: The House and Senate are back in session with two weeks to go until the government funding deadline and lots to do.
Insight: original analysis
Welcome to September!
Insight: original analysis
One chamber down. One to go before the August recess.
Insight: original analysis
This Week’s Dose: The Senate Finance Committee finally released its drug pricing package and moved quickly to a markup. The bill passed out of committee, but work will continue before the full Senate votes. We’ll be watching closely as things develop.
Insight: original analysis
This is the last scheduled week the House is in session and the second to last week the Senate is in session before the August recess. What will get done?
Insight: original analysis
We head into another critical week before August recess.
Insight: original analysis
This Week’s Dose: Congress is back for the final legislative session before the August recess, and it’s all about what can get done ahead of the break. House and Senate committees have already advanced a cost containment legislation that includes surprise billing and prescription drug cost provisions, among many other things. We still await any…
Insight: original analysis
They’re back… and heading into the final weeks before the August recess.
Insight: original analysis
This Week’s Dose: Lots of movement in Congress ahead of the Fourth of July recess with the House and Senate both advancing a number of health care bills. President Trump also signed an executive order this week, continuing the Administration’s focus on health care transparency.
Insight: original analysis
This Week’s Dose: Three weeks down, one week to go in this work period. The Senate Health, Education, Labor and Pensions (HELP) Committee is moving forward with its cost containment legislation, and the House passed the first batch of health care extenders.
Insight: original analysis
On June 19, 2019, the US Senate Committee on Health, Education, Labor & Pensions (HELP) released its updated Lower Health Care Costs Act (S. 1895). This new version includes several noteworthy changes, outlined below.
Insight: original analysis
Two weeks down. Two weeks to go.
Insight: original analysis
This Week’s Dose: Congress is back, and this week marked the start of another busy legislative session. Work continues on drug pricing, surprise billing and cost containment, and negotiations have begun on an extenders package as well.
Insight: original analysis
Since mid-2018, the Centers for Medicare and Medicaid Services has been implementing sections of the American Patients First Blueprint, President Trump’s plan to lower drug prices and reduce patient out-of-pocket spending.
Insight: original analysis
This Week’s Dose: We saw a flurry of activity this week related to drug pricing, surprise billing, cost containment and tobacco as lawmakers worked through their to-do list ahead of the Memorial Day recess.
Insight: original analysis
This Week’s Dose: Drug pricing remains in the spotlight, but lawmakers also introduced legislation focused on surprise billing and coinsurance.
Insight: original analysis
We are half way through this four week work stretch…
Insight: original analysis
This Week’s Dose: Another busy week for prescription drug pricing. Two more hearings took place on the subject, and a handful of bills passed out of the House. Now we watch the Senate to see how it packages and advances prescription drug bills that have moved through the House.
Insight: original analysis
This Week’s Dose: Lots of activity surrounding single-payer this week with a hearing, the introduction of two Medicare expansion bills and a report from the Congressional Budget Office (CBO). Hearings and markups of drug pricing bills continue as well. This legislative session is off to a busy start.
Insight: original analysis
Let me count the ways to 100. 1. Affordable Care Act. 2. Insurance Expansion. 3. Drug Pricing. 4. Surprise Billing. 5… Ok, maybe let me count to four.
Insight: original analysis
This Week’s Dose: Drug pricing continues to be the focus in Congress with multiple hearings and markups on the subject. So far, lowering drug prices remains a rare area of consensus among lawmakers.
Insight: original analysis
This Week’s Dose: Congress is back and busy. The ACA dominates the headlines.
Insight: original analysis
This Week’s Diagnosis: All about the budget. Medicaid work requirements back in the spotlight. Recess awaits.
Insight: original analysis
On March 11, 2019, the White House released its FY 2020 budget proposal. In the area of health care, the president has requested $87.1 billion in discretionary budget authority for HHS, which represents a 12 percent decrease from the 2019 estimated level. Read on for key HHS proposal highlights.
Insight: original analysis
This Week’s Diagnosis: Hearings, hearings and more hearings. FDA Commissioner Scott Gottlieb is stepping down. Budget talks heat up.
Insight: original analysis
This Week’s Diagnosis: It’s all quiet on the Hill. Members return Monday after the first full week of district work time in the 116th Congress.
Insight: original analysis
This Week’s Diagnosis: Congress passed a $328 billion spending package to avert another government shutdown. President Trump is expected to sign it. Congressional hearings continue to focus on coverage and drug pricing.
Insight: original analysis
This Week’s Dose: The State of the Union briefly highlighted a few Administration health initiatives. The House continues its focus on the Affordable Care Act (ACA). The Senate is pressuring CEOs from the largest drug manufacturers to testify.
Insight: original analysis
This Week’s Diagnosis: Government reopens…for at least three weeks. Congress is full steam ahead, kicking off the 116th with health care hearings on drug pricing and pre-existing conditions. The US Department of Health and Human Services focuses on 2019 priorities.
Insight: original analysis
This Week’s Diagnosis: Hearings are beginning and priorities are emerging. The shutdown drags on. And updates are trickling out of the Administration.
Insight: original analysis
This Week’s Diagnosis: Welcome back – sort of. The partial federal government shutdown drags on. We are on day 21 with no end in sight, which has shifted the focus of the new Congress away from overarching health priorities and toward continued efforts to reopen the government.
Insight: original analysis
This Week’s Diagnosis: Memorial services for President George H.W. Bush were held this week in Washington, DC and Texas. No agreement has been reached on border wall funding, which means Members may be here through at least December 21.
Insight: original analysis
This Week’s Diagnoses: Welcome back! Members are back in town for a sprint to the finish. Controversy over the House Democratic leadership elections fizzled, with the same faces in the top three positions.
Insight: original analysis
Democrats will take control of the House of Representatives in January 2019. Republicans will retain control of the Senate, widening their margin slightly. Split control of Congress will have important consequences for healthcare policy. This article takes a closer look at how the election is likely to impact the health policy agenda.
Insight: original analysis
This Week’s Diagnosis: The Administration remains active with the issuance of several new guidance documents, the drug pricing announcement and the President (finally) signing the bipartisan opioid legislation (HR 6).
Insight: original analysis
This Week’s Diagnoses: All eyes are on the midterm election, now less than three weeks away. The House and Senate are out; the Administration continues to release health-related regulations and announcements.
Insight: original analysis
This Week’s Diagnosis: Consideration of the Kavanaugh nomination dominated airtime in the Senate this week, but the House stayed on-task, pushing through a number of health-related bills.
Insight: original analysis
This article—the latest in a McDermott+Consulting series investigating the president’s drug pricing plans—takes a closer look at Oklahoma’s recently approved State Plan Amendment that allows Oklahoma to negotiate value-based contracts with drug makers for individuals covered by the state’s Medicaid plan.
Insight: original analysis
On May 11, 2018, President Trump released the American Patients First Blueprint, a plan to lower drug prices and reduce beneficiary out-of-pocket spending on drugs in the Medicare program.
Insight: original analysis
Since the run-up to the 2016 presidential election, Donald Trump has stated his interest in controlling and lowering the high cost of prescription drugs. Until recently his administration had released limited details on possible ways to do so.